By administering B12-drug conjugates, bound to IF, it is a strong hypothesis therefore, that it will deliver the drug to cells/tissues/organs that express cubilin. For example, by injecting a B12-PET imaging probe you would likely see sequestration in the kidneys. An extension on this idea has recently been shown utilizing IF produced in the plant by Xeragenx. Due to changes in the glycosylation pattens between Human IF produced endogenously and human IF produced in the plant, IF-B12-PET probe sequesters cleanly and clearly to the liver - a process likely mediated by a sugar receptor CD206. Targeting CD206 is an exciting current area of drug development, given its tie to inflammatory response.